Artemisinin-based combination therapy for ... - The Cochrane Library

7.4 Total Failure Day 28
PCR adjusted (new infections
included as successes)
7.5 Total Failure Day 28 PCR
adjusted (losses to follow up
included as failures)
7.6 Total Failure Day 28 PCR
adjusted (losses to follow up
included as successes)
2 382 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.29, 1.17]
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.48, 1.23]
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.30, 1.17]
Comparison 11. Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 East Africa 3 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.30, 0.41]
1.2 West Africa 3 1130 Risk Ratio (M-H, Fixed, 95% CI) 2.88 [1.86, 4.47]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 East Africa 2 618 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.06, 0.24]
2.2 West Africa 3 1051 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.55, 3.47]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 West Africa 1 345 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.66, 4.21]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 West Africa 1 284 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.44, 3.38]
5 Gametocyte carriage 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gametocyte carriage day 0 4 1545 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.51, 1.39]
5.2 Gametocyte carriage day 3 3 1331 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.25, 0.75]
5.3 Gametocyte carriage day 7 4 1538 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.18, 0.54]
5.4 Gametocyte carriage day
14
4 1536 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.21, 1.01]
6 Gametocyte development (in
those negative at baseline)
1 371 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.08, 1.04]
7 Anaemia 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Mean haemoglobin (g/dl)
at baseline
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.2 Mean change in
haemoglobin (g/dl) from
baseline to Day 28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.3 Mean haemoglobin (g/dl)
at Day 42 or last day of follow
up.
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Serious adverse events (including
deaths)
5 2684 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.08]
9 Early vomiting 2 893 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.54, 3.68]
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
118